<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00794989</url>
  </required_header>
  <id_info>
    <org_study_id>I 81906</org_study_id>
    <secondary_id>RPCI-I-81906</secondary_id>
    <secondary_id>11-0575</secondary_id>
    <nct_id>NCT00794989</nct_id>
  </id_info>
  <brief_title>Flaxseed in Preventing Breast Cancer in Premenopausal Women at Risk of Developing Breast Cancer</brief_title>
  <official_title>A Study Evaluating the Effect of Flaxseed on Biomarkers of Breast Cancer Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Ground flaxseed may prevent breast cancer in premenopausal women at increased risk&#xD;
      of developing primary breast cancer.&#xD;
&#xD;
      PURPOSE: This randomized clinical trial is studying how well flaxseed works in preventing&#xD;
      breast cancer in premenopausal women at risk of breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary aims:&#xD;
&#xD;
        -  Determine if 25 grams of flaxseed supplementation daily&#xD;
&#xD;
             -  modifies proliferation (ki-67) and apoptotic rates after six months&#xD;
&#xD;
             -  modifies expression of estrogen regulated genes: Cyclin D1, survivin, and VEGF at&#xD;
                six months&#xD;
&#xD;
             -  modifies serum IGF-1 and serum binding protein (IGFBP)-3 levels from baseline to 6&#xD;
                months&#xD;
&#xD;
             -  and evaluate the feasibility and tolerability of flaxseed consumption, and&#xD;
                determine factors that lead to decreased compliance&#xD;
&#xD;
      STUDY OUTLINE:&#xD;
&#xD;
      This is a randomized study. Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
        -  Arm I (intervention): Patients ingest 25 grams ground flaxseed daily, with already&#xD;
           prepared foods, for 6 months. Patients are instructed to record the time and with what&#xD;
           foods flaxseed is consumed, and the number of bowel movements daily. Throughout the&#xD;
           6-month intervention period, patients also complete unannounced telephone-administered&#xD;
           surveys recounting all foods and beverages consumed within the previous 24 hours.&#xD;
&#xD;
        -  Arm II (observation): Patients do not receive ground flaxseed. All patients complete a&#xD;
           diary about menstrual cycle duration and presence or improvement of premenstrual&#xD;
           symptoms (e.g., cramping, bloating, headache, insomnia, or other irregular symptoms).&#xD;
           Patients also complete questionnaires at 1, 3, and 6 months to access changes in diet,&#xD;
           physical activity, menstrual history, demographic characteristics, and medical history&#xD;
           and a specimen questionnaire at baseline and at 1, 3, and 6 months.&#xD;
&#xD;
      Blood and first-void urine samples are collected at baseline and at 1, 3, and 6 months to&#xD;
      measure levels of lignan metabolites, flaxseed compliance, serum thiocyanate,&#xD;
      malondialdehyde, and for biomarker studies by capillary gas chromatography-mass spectrometry,&#xD;
      high-performance liquid chromatography, and ELISA.&#xD;
&#xD;
      After completion of study therapy, patients are followed monthly for up to 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual&#xD;
  </why_stopped>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alteration in intermediate biomarkers of breast cancer risk at baseline and at 1, 3, and 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability and compliance</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Precancerous Condition</condition>
  <arm_group>
    <arm_group_label>Arm 1: Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients ingest ground flaxseed daily, with already prepared foods, for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Observational</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients do not receive ground flaxseed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ground Flaxseed</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm 1: Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention</intervention_name>
    <description>Participants randomized to Arm 2 do not receive any intervention</description>
    <arm_group_label>Arm 2: Observational</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Patients enrolled in must meet ≥ 1 of the following criteria:&#xD;
&#xD;
               -  History of unilateral or bilateral atypical ductal hyperplasia with or without&#xD;
                  family history&#xD;
&#xD;
               -  History of atypical lobular hyperplasia or lobular carcinoma in situ with or&#xD;
                  without family history&#xD;
&#xD;
               -  History of ductal carcinoma in situ&#xD;
&#xD;
               -  Prior stage I breast cancer allowed provided it was adequately treated and&#xD;
                  therapy was completed ≥ 1 year ago&#xD;
&#xD;
               -  Lifetime risk for developing breast cancer &gt; 20% (based on Gail or Claus model)&#xD;
&#xD;
               -  No abnormal mammogram requiring short-term follow-up within the past 6 months&#xD;
&#xD;
               -  No severe atypia or carcinoma cells on RPRNA&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Premenopausal&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Patients enrolled must meet the following criteria:&#xD;
&#xD;
               -  No peri- or postmenopausal status as determined by estradiol levels &lt; 20 ng/dL&#xD;
                  and FSH levels &gt; 45 ng/dL&#xD;
&#xD;
               -  No thrombocytopenia (defined as platelet count &lt; 50,000/mm^3)&#xD;
&#xD;
               -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
               -  Not pregnant or nursing&#xD;
&#xD;
               -  Fertile patients must use effective contraception consistently&#xD;
&#xD;
               -  No other prior malignancy allowed except for the following:&#xD;
&#xD;
                    -  Basal cell or squamous cell carcinoma&#xD;
&#xD;
                    -  In situ cervical cancer&#xD;
&#xD;
               -  No history of any of the following conditions within the past 5 years:&#xD;
&#xD;
                    -  Crohn disease&#xD;
&#xD;
                    -  Ulcerative colitis&#xD;
&#xD;
                    -  Inflammatory bowel disease&#xD;
&#xD;
                    -  Irritable bowel syndrome&#xD;
&#xD;
                    -  Celiac sprue&#xD;
&#xD;
                    -  Malabsorption syndrome&#xD;
&#xD;
                    -  Diverticulitis&#xD;
&#xD;
                    -  Diverticulosis&#xD;
&#xD;
               -  No allergy to flaxseed, other seeds or nuts, or wheat&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Patients enrolled in part 1 must meet the following criteria:&#xD;
&#xD;
               -  No prior breast implants or tram-flap reconstruction&#xD;
&#xD;
                    -  Breast reduction allowed&#xD;
&#xD;
               -  No prior neoadjuvant chemotherapy or other chemotherapy within the past year&#xD;
&#xD;
               -  No prior neoadjuvant hormonal therapy&#xD;
&#xD;
               -  No prior whole radiation to the contralateral breast undergoing random&#xD;
                  periareolar fine needle aspiration (RPFNA)&#xD;
&#xD;
               -  No concurrent coumadin or other chronic anticoagulants (even if they are held for&#xD;
                  surgery)&#xD;
&#xD;
          -  Patients enrolled in part 2 must meet the following criteria:&#xD;
&#xD;
               -  More than 1 year since prior chemotherapy and adjuvant hormonal therapy for&#xD;
                  breast cancer&#xD;
&#xD;
                    -  No concurrent chemotherapy for breast cancer&#xD;
&#xD;
               -  At least 1 month since prior and no concurrent treatment with corticosteroid&#xD;
&#xD;
               -  At least 2 weeks since prior and no concurrent use of antibiotics&#xD;
&#xD;
               -  At least 2 weeks&#xD;
&#xD;
               -  No history of chest wall irradiation&#xD;
&#xD;
               -  No presence of breast implants&#xD;
&#xD;
               -  No prior or concurrent tamoxifen within the past 90 days&#xD;
&#xD;
               -  No chronic/concurrent medications that inhibit platelet function, including any&#xD;
                  of the following:&#xD;
&#xD;
                    -  Aspirin&#xD;
&#xD;
                    -  Non-steroidal anti-inflammatory drugs (i.e., Aleve®, Motrin®, ibuprofen)&#xD;
&#xD;
                    -  Coumadin&#xD;
&#xD;
                    -  Heparin&#xD;
&#xD;
                    -  Low molecular weight heparin&#xD;
&#xD;
                    -  Anti-platelet agents&#xD;
&#xD;
                         -  No prior short-term use of platelet inhibitors ≥ 7 days prior to RPFNA&#xD;
&#xD;
               -  No concurrent ingestion of the following:&#xD;
&#xD;
                    -  Pumpkin seeds&#xD;
&#xD;
                    -  Sesame seeds&#xD;
&#xD;
                    -  Fish oil supplements&#xD;
&#xD;
               -  At least 30 days since prior and no concurrent flaxseed supplements, fish oil, or&#xD;
                  flaxseed oil&#xD;
&#xD;
               -  No concurrent treatment for another malignancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Swati Kulkarni, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Cancer Park Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>November 20, 2008</study_first_submitted>
  <study_first_submitted_qc>November 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2008</study_first_posted>
  <last_update_submitted>June 1, 2016</last_update_submitted>
  <last_update_submitted_qc>June 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>atypical ductal breast hyperplasia</keyword>
  <keyword>lobular breast carcinoma in situ</keyword>
  <keyword>ductal breast carcinoma in situ</keyword>
  <keyword>breast cancer prevention</keyword>
  <keyword>high risk breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

